A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

NCT02399137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: MM-141
DRUG: Placebo
DRUG: Gemcitabine
DRUG: Nab-Paclitaxel

Sponsor

Merrimack Pharmaceuticals